Mirtazapine (Remeron) for Akathisia
Mirtazapine at low doses (15 mg daily) is effective for treating antipsychotic-induced akathisia and should be considered as a first-line option, particularly when beta-blockers are contraindicated or poorly tolerated.
Evidence-Based Recommendation
The most recent international guidelines 1 and APA guidelines 2 recommend standard approaches for akathisia management: dose reduction, switching to quetiapine or olanzapine, or adding propranolol (10-30 mg two to three times daily) or benzodiazepines. However, mirtazapine is not mentioned in current major guidelines, despite robust research evidence supporting its efficacy.
Research Evidence Supporting Mirtazapine
The strongest evidence comes from a 2015 meta-analysis 3 of randomized placebo-controlled trials (n=86) demonstrating:
- Response rate: Risk ratio 6.67 (95% CI 2.14-20.78, p=0.001)
- Complete remission: Risk ratio 6.20 (95% CI 1.74-22.08, p=0.005)
- Number needed to treat: 4 for partial response, 5 for complete remission
A head-to-head trial 4 comparing mirtazapine 15 mg versus propranolol 80 mg versus placebo over 7 days (n=90) showed:
- Mirtazapine reduced akathisia severity by 34% (vs. 11% placebo, p=0.012)
- Response rate: 43.3% for mirtazapine vs. 30% for propranolol vs. 6.7% for placebo
- Critical advantage: Zero cardiovascular adverse events with mirtazapine vs. 16.7% discontinuation rate with propranolol due to hypotension/bradycardia
Mechanism and Dosing
Mirtazapine's efficacy stems from its potent 5-HT2A/2C receptor antagonism, similar to other effective agents like ritanserin and mianserin. The FDA label 5 lists akathisia as a rare adverse event (<1/1000), but this refers to mirtazapine-induced akathisia, not its therapeutic use.
Optimal dosing:
- Standard dose: 15 mg daily 4, 6
- Ultra-low dose: 7.5 mg may be effective with better tolerability 7, though evidence is limited to retrospective data
- Duration: Improvement typically seen within 3-5 days
Clinical Algorithm
First-line options (choose based on patient factors):
- If cardiovascular disease, elderly, or risk of hypotension: Mirtazapine 15 mg at bedtime
- If no cardiovascular concerns: Propranolol 10-30 mg TID or mirtazapine
- Consider benzodiazepines for acute distress
If propranolol fails or causes adverse effects: Switch to mirtazapine 15 mg
If mirtazapine causes excessive sedation: Trial 7.5 mg dose
Concurrent strategies: Reduce antipsychotic dose if clinically feasible, or switch to quetiapine/olanzapine 1
Important Caveats
- Sedation and weight gain are common with mirtazapine 5, 8. Sedation affects >50% at antidepressant doses but may be less problematic at 15 mg for akathisia
- Particularly effective for aripiprazole-induced akathisia 7
- A 2024 case report 9 demonstrated efficacy even in severe, treatment-resistant akathisia unresponsive to benzodiazepines and anticholinergics
- Drug interactions: Carbamazepine and phenytoin reduce mirtazapine levels by ~50-60%; ketoconazole increases levels by 40-50% 5
Quality of Life Considerations
Mirtazapine offers superior tolerability compared to propranolol in patients with cardiovascular vulnerability, avoiding bradycardia and hypotension that can significantly impair function. The sedating effects, while potentially problematic, can be beneficial for patients with comorbid insomnia. Weight gain risk must be weighed against the severe distress and functional impairment caused by untreated akathisia, which can lead to medication non-adherence and relapse.